NO20072687L - Pharmaceutical contraceptive preparation - Google Patents
Pharmaceutical contraceptive preparationInfo
- Publication number
- NO20072687L NO20072687L NO20072687A NO20072687A NO20072687L NO 20072687 L NO20072687 L NO 20072687L NO 20072687 A NO20072687 A NO 20072687A NO 20072687 A NO20072687 A NO 20072687A NO 20072687 L NO20072687 L NO 20072687L
- Authority
- NO
- Norway
- Prior art keywords
- daily dosage
- ethinyl estradiol
- administered
- dienogest
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Oppfinnelsen vedrører et farmasøytisk preparat som inneholder dienogest ved en mengde som tilsvarer en daglig doseringsenhet på 1,5 mg eller 2,0 mg når preparatet blir administrert, og etinyløstradiol ved en mengde som tilsvarer en daglig doseringsenhet på 0,015 mg eller 0,020 mg når preparatet blir administrert, sammen med én eller flere farmasøytisk akseptable bærere i minst 21 daglige doseringsenheter. Oppfinnelsen vedrører ytterligere et oralt, farmasøytisk prevensjonspreparat inneholdende 1,5 mg 17a-cyanometyl-17ß-hydroksyøstra-4,9-dien-3-on (dienogest) og 0,015 eller 0,020 mg 17a-etinyløstradiol (etinyløstradiol) eller 2,0 mg dienogest og 0,015 mg etinyløstradiol sammen med én eller flere farmasøytisk akseptable bærer i minst 21 daglige doseringsenheter i en 28-dagers menstruasjonssyklus.The invention relates to a pharmaceutical composition containing dienogest at an amount corresponding to a daily dosage unit of 1.5 mg or 2.0 mg when administered, and ethinyl estradiol at an amount corresponding to a daily dosage unit of 0.015 mg or 0.020 mg when the preparation is administered. administered with one or more pharmaceutically acceptable carriers in at least 21 daily dosage units. The invention further relates to an oral pharmaceutical contraceptive composition containing 1.5 mg of 17α-cyanomethyl-17β-hydroxyester-4,9-dien-3-one (dienogest) and 0.015 or 0.020 mg of 17α-ethinyl estradiol (ethinyl estradiol) or 2.0 mg dienogest and 0.015 mg of ethinyl estradiol together with one or more pharmaceutically acceptable carriers in at least 21 daily dosage units during a 28-day menstrual cycle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05003179A EP1690543A1 (en) | 2005-02-15 | 2005-02-15 | Pharmaceutical composition for contraception |
| PCT/EP2006/001354 WO2006087173A1 (en) | 2005-02-15 | 2006-02-15 | Contraceptive pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072687L true NO20072687L (en) | 2007-11-13 |
Family
ID=34933759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072687A NO20072687L (en) | 2005-02-15 | 2007-05-25 | Pharmaceutical contraceptive preparation |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP1690543A1 (en) |
| JP (1) | JP2008527018A (en) |
| KR (1) | KR20070086380A (en) |
| CN (1) | CN101119732A (en) |
| AR (1) | AR053545A1 (en) |
| AU (1) | AU2006215818A1 (en) |
| BR (1) | BRPI0606724A2 (en) |
| CA (1) | CA2590004A1 (en) |
| CR (1) | CR9324A (en) |
| DO (1) | DOP2006000035A (en) |
| EA (1) | EA200701091A1 (en) |
| IL (1) | IL183635A0 (en) |
| MX (1) | MX2007009061A (en) |
| NO (1) | NO20072687L (en) |
| PA (1) | PA8663401A1 (en) |
| PE (1) | PE20061291A1 (en) |
| TW (1) | TW200640468A (en) |
| UA (1) | UA85003C2 (en) |
| WO (1) | WO2006087173A1 (en) |
| ZA (1) | ZA200707910B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1774970A1 (en) * | 2005-10-13 | 2007-04-18 | Bayer Schering Pharma AG | Method for preparing a monophase pharnmaceutical preparation containing ethinyl estradiol and dienogest for the treatment of dysfunctional uterine bleeding |
| DE102008051140B4 (en) * | 2007-10-11 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | A process for the preparation of a monophasic pharmaceutical preparation for limiting / reducing the risk of deep vein thrombosis in unit with oral contraception |
| AT12800U1 (en) * | 2007-11-05 | 2012-11-15 | Bayer Schering Pharma Ag | A pharmaceutical preparation for use in the oral contraception of lactose intolerant women |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998004269A1 (en) * | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen |
-
2005
- 2005-02-15 EP EP05003179A patent/EP1690543A1/en not_active Withdrawn
-
2006
- 2006-02-13 DO DO2006000035A patent/DOP2006000035A/en unknown
- 2006-02-15 PE PE2006000182A patent/PE20061291A1/en not_active Application Discontinuation
- 2006-02-15 AU AU2006215818A patent/AU2006215818A1/en not_active Abandoned
- 2006-02-15 TW TW095105106A patent/TW200640468A/en unknown
- 2006-02-15 WO PCT/EP2006/001354 patent/WO2006087173A1/en not_active Ceased
- 2006-02-15 EA EA200701091A patent/EA200701091A1/en unknown
- 2006-02-15 CN CNA2006800048911A patent/CN101119732A/en active Pending
- 2006-02-15 MX MX2007009061A patent/MX2007009061A/en not_active Application Discontinuation
- 2006-02-15 KR KR1020077013786A patent/KR20070086380A/en not_active Ceased
- 2006-02-15 BR BRPI0606724-7A patent/BRPI0606724A2/en not_active IP Right Cessation
- 2006-02-15 EP EP06706958A patent/EP1853273A1/en not_active Ceased
- 2006-02-15 UA UAA200709517A patent/UA85003C2/en unknown
- 2006-02-15 PA PA20068663401A patent/PA8663401A1/en unknown
- 2006-02-15 JP JP2007551646A patent/JP2008527018A/en not_active Withdrawn
- 2006-02-15 CA CA002590004A patent/CA2590004A1/en not_active Abandoned
- 2006-02-15 AR ARP060100527A patent/AR053545A1/en unknown
-
2007
- 2007-05-25 NO NO20072687A patent/NO20072687L/en not_active Application Discontinuation
- 2007-06-04 IL IL183635A patent/IL183635A0/en unknown
- 2007-08-17 CR CR9324A patent/CR9324A/en unknown
- 2007-09-14 ZA ZA200707910A patent/ZA200707910B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006087173A1 (en) | 2006-08-24 |
| EA200701091A1 (en) | 2008-02-28 |
| UA85003C2 (en) | 2008-12-10 |
| IL183635A0 (en) | 2007-10-31 |
| TW200640468A (en) | 2006-12-01 |
| CN101119732A (en) | 2008-02-06 |
| PE20061291A1 (en) | 2006-12-07 |
| PA8663401A1 (en) | 2006-12-07 |
| MX2007009061A (en) | 2007-09-11 |
| AU2006215818A1 (en) | 2006-08-24 |
| BRPI0606724A2 (en) | 2009-07-14 |
| CR9324A (en) | 2007-10-11 |
| EP1690543A1 (en) | 2006-08-16 |
| CA2590004A1 (en) | 2006-08-24 |
| KR20070086380A (en) | 2007-08-27 |
| ZA200707910B (en) | 2009-08-26 |
| DOP2006000035A (en) | 2006-09-15 |
| JP2008527018A (en) | 2008-07-24 |
| AR053545A1 (en) | 2007-05-09 |
| EP1853273A1 (en) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2558030T3 (en) | Long-cycle multiphase oral contraceptive method | |
| HRP20070188B1 (en) | PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR USE AS A CONTRACEPTIC | |
| EA200900491A1 (en) | USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN | |
| BG66095B1 (en) | Pregelatinized starch in a controlled release preparation | |
| NO327588B1 (en) | Pharmaceutical composition and composition comprising ethinylostradiol and drospirenone for use as a contraceptive | |
| NO20072893L (en) | Solid oral contraceptive | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| CR9324A (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| WO2005092441A3 (en) | Extended cycle multiphasic oral contraceptive method | |
| TW200638951A (en) | Solid oral pharmaceutical form for contraception | |
| NO20091057L (en) | Oral form of birth control | |
| UY29378A1 (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| CY1112775T1 (en) | USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA | |
| TH80557A (en) | Pharmaceutical products for oral contraception | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive | |
| RU2009140372A (en) | NEW MODE WITH DROSPIRENONE / 17B-ESTRADIOL, PHARMACEUTICAL COMBINED PRODUCT AND KIT FOR THE PERFORMANCE OF THIS MODE | |
| HRP20020666B1 (en) | DROSPIRENON FOR HORMONAL REPLACEMENT THERAPY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |